The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Immunotherapy in MPNs: antibodies, CAR-T, and more
In this video, Tania Jain, MBBS, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, outlines the topics covered in her talk on immunotherapy in myeloproliferative neoplasms (MPNs) at the 2025 MPN Workshop of the Carolinas. Dr Jain highlights the promising directions being investigated in this area, including several mutant calreticulin (mutCALR)-targeted therapies, CAR T-cell therapy approaches, and the use of healthy donor-derived T-cells for preventing post-transplant relapse. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So immunotherapy is an evolving field in oncology and a very exciting one of that. And I’m glad that it’s finally making its way into MPNs. We talked about the CALR-directed or mutant CALR-directed antibody, which is not quite immunotherapy, but targeted therapy, kind of an overlapping-ish cousin. But it has shown some nice early clinical data and safety in ET patients...
So immunotherapy is an evolving field in oncology and a very exciting one of that. And I’m glad that it’s finally making its way into MPNs. We talked about the CALR-directed or mutant CALR-directed antibody, which is not quite immunotherapy, but targeted therapy, kind of an overlapping-ish cousin. But it has shown some nice early clinical data and safety in ET patients. We’ll learn more about the ET data and hopefully more about the myelofibrosis data at ASH.
We next talked about T-cell redirecting antibodies, so more like bispecifics or T-cell engagers, where you’re bringing the mutant CALR on one end and the T-cells on the other end to bring them in close proximity so that the T-cells can kill the mutant cells. And that’s ongoing in a clinical trial with the JNJ BiTE and a clinical, a Phase I clinical trial with Incyte that is on its way to open.
We talked about CAR-Ts in MPNs. So in Europe at University College London, they’re exploring the possibility of mutant CALR-directed CAR-T, which was presented last year as a concept, and we’ll see how the clinical responses and safety pan out there. We’re working on a SLAMF7-directed CAR-T. As you know, elotuzumab was a naked antibody that was targeting SLAMF7-explored in myelofibrosis with some efficacy. But obviously with the CAR-T, you’ll be hitting it stronger. You’ll be hitting it with the downstream T-cell activation.
And lastly, most importantly, about transplant and relapse prevention post-transplant, that’s somewhere that’s this place where you can harness the donor immune system which is healthy T-cells, which you can activate or engineer to target recipient leukemic stem cells or recipient hematopoietic stem cells in a post-transplant period, so that they can be targeted and any residual recipient stem cells can be can be cleared off.
So those are the things we talked about. A lot of these are concepts. A lot of these we need a much longer follow-up to understand how this how they eventually impact the field. Exciting nevertheless.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Institutional research support from CTI Biopharma, Kartos therapeutics, Incyte, Tscan, Karyopharm Therapeutics; Advisory board participation: Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics, Galapagos, Tscan therapeutics, Karyopharm, Morphosys, In8Bio.
